GlassScriptPhysician profile
Michael Pfister Smith
NPI 1487039970
$18,247.96
in general payments reported to CMS, 2019-2025
49 companies · $3,523 in 2025
The $3,523 reported for 2025 was more than what 81% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $218 · 2022: $1,172 · 2023: $3,180 · 2024: $10K · 2025: $3,523.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,563.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,295.65 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,562.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $7,811.49 | 2021-2025 | Qulipta |
| Sumitomo Pharma America, INC. | $1,118.16 | 2023 | Aptiom |
| Ucb, INC. | $1,088.97 | 2023-2025 | Fintepla, Briviact, Zilbrysq |
| Lundbeck LLC | $638.26 | 2022-2025 | Vyepti |
| Alexion Pharmaceuticals, INC. | $553.78 | 2023-2025 | Ultomiris, Soliris |
| Amgen INC. | $470.98 | 2021-2025 | Uplizna |
| Argenx US, INC. | $456.85 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Ge Healthcare | $374.88 | 2022-2025 | |
| Emd Serono, INC. | $365.96 | 2022-2025 | Mavenclad |
| Horizon Therapeutics Plc | $327.31 | 2022-2023 | Uplizna |
| Acadia Pharmaceuticals INC | $321.99 | 2022-2025 | Nuplazid, Daybue |
| Novartis Pharmaceuticals Corporation | $316.50 | 2023-2024 | |
| Pfizer INC. | $304.71 | 2023-2025 | |
| Eisai INC. | $293.64 | 2022-2025 | |
| Neurocrine Biosciences, INC. | $289.34 | 2024-2025 | Ingrezza |
Show all 49 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $279.27 | 2023-2025 | Hizentra, Kcentra |
| Jazz Pharmaceuticals INC. | $274.74 | 2024-2025 | |
| Neurelis, INC. | $264.80 | 2022-2025 | Valtoco |
| Takeda Pharmaceuticals U.S.A., INC. | $249.37 | 2022-2025 | Hyqvia |
| Catalyst Pharmaceuticals, INC. | $247.26 | 2023-2025 | Firdapse |
| Lilly USA, LLC | $243.81 | 2022-2025 | Amyvid, Kisunla, Emgality |
| Genentech USA, INC. | $227.59 | 2023-2025 | Ocrevus Zunovo, Ocrevus |
| Sk Life Science, INC. | $218.23 | 2024-2025 | Xcopri |
| Genzyme Corporation | $189.46 | 2023-2024 | |
| Teva Pharmaceuticals USA, INC. | $109.77 | 2022-2025 | Austedo Xr, Austedo Xr |
| Amneal Pharmaceuticals LLC | $109.08 | 2022-2024 | Rytary |
| Janssen Biotech, INC. | $106.39 | 2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $99.45 | 2022 | |
| Mdd US Operations, LLC | $95.70 | 2023-2025 | Gocovri, Gocovri, Qelbree |
| Avion Pharmaceuticals | $90.93 | 2021-2023 | Dhivy |
| Scilex Pharmaceuticals INC. | $87.55 | 2024 | |
| Biogen, INC. | $72.80 | 2024-2025 | Vumerity, Tysabri |
| Otsuka America Pharmaceutical, INC. | $70.07 | 2023-2025 | Rexulti, Nuedexta |
| Octapharma USA, INC. | $67.55 | 2022-2023 | Panzyga |
| Kyowa Kirin, INC. | $57.83 | 2023-2024 | Nourianz |
| Biohaven Pharmaceuticals, INC. | $37.13 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $36.63 | 2023-2025 | Andexxa, Wainua |
| Tg Therapeutics, INC. | $32.88 | 2025 | |
| Almatica Pharma LLC | $32.75 | 2022 | |
| Acorda Therapeutics, INC | $28.62 | 2024 | Ampyra, Inbrija |
| Vanda Pharmaceuticals INC. | $26.58 | 2024 | Ponvory |
| Aquestive Therapeutics, INC. | $26.47 | 2021 | |
| Alnylam Pharmaceuticals INC. | $26.43 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $21.55 | 2023 | Dysport |
| Medtronic, INC. | $20.43 | 2024 | Intellis Adaptivestim |
| C2n Diagnostics, LLC | $19.78 | 2025 | Precivityad2 |
| Sandoz INC. | $16.47 | 2023 | |
| Kedrion Biopharma, INC. | $14.08 | 2025 | Rhogam Ultra-Filtered Plus, Albuked, Gammaked |
| Mallinckrodt Hospital Products INC. | $13.69 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.